"Developing a treatment for mesothelioma also opens up the Orphan Drug Program for the company. This is a program that results in a much more expeditious route to market with a reduced program of clinical testing and a fast track through the regulatory process. E.g. the Novartis product Gleevac took 9 weeks to pass through the US FDA where the average approval time is 29 months."
Remember, this is only 1 (certainly the main one) of the products under development by Solbec. Visit their website www.solbec.com.au to get the FULL picture; then understand that Orphan Drug Status is not the only matter that can move the price upwards.
SBP Price at posting:
0.0¢ Sentiment: None Disclosure: Held
